Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Cardiovascular Complications and COVID-19 (CovCardioVasc-Study) (CovCardioVasc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04335162
Recruitment Status : Unknown
Verified April 2020 by Centre Hospitalier Universitaire de Nice.
Recruitment status was:  Recruiting
First Posted : April 6, 2020
Last Update Posted : November 24, 2020
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice

Brief Summary:
Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

Condition or disease
COVID Acute Coronary Syndrome Myocardial Infarction Myocarditis Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Cardiovascular Complications in Patients With COVID-19
Actual Study Start Date : February 28, 2020
Estimated Primary Completion Date : August 31, 2021
Estimated Study Completion Date : August 31, 2021

Resource links provided by the National Library of Medicine

Patients with cardiovascular complications
Patients presenting with cardiomyopathies or venous thromboembolism
Patients without cardiovascular complications
Patients without cardiomyopathies or venous thromboembolism
Intensive Care Unit patients
Patients admitted in intensive care unit
Hospital Ward patients
Patients admitted in hospital ward

Primary Outcome Measures :
  1. Determine the incidence of cardiomyopathies and venous thromboembolism [ Time Frame: 28 days ]
    Incidence of cardiomyopathies and/or venous thromboembolism at day 28

Secondary Outcome Measures :
  1. Mortality [ Time Frame: 28 days ]
    Incidence of mortality at day 28

  2. Duration of mechanical ventilation [ Time Frame: hospitalisation duration ]
    Number of day of using mechanical ventilation for each patients

  3. Shock [ Time Frame: hospitalisation duration ]
    Incidence of shock during hospitalisation

  4. length of stay [ Time Frame: hospitalisation duration ]
    Number of day at hospital

  5. Mechanical ventilation [ Time Frame: hospitalisation duration ]
    Setting up or not of mechanical ventilation

  6. Renal replacement therapy [ Time Frame: hospitalisation duration ]
    Administration or not of renal replacement therapy

Biospecimen Retention:   Samples Without DNA
whole blood

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Non-Probability Sample
Study Population
Intensive care unit, hospital ward

Inclusion Criteria:

- All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be included

Exclusion Criteria:

- Patients under 18 years

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04335162

Layout table for location contacts
Contact: Denis DOYEN 0033492035510

Layout table for location information
Centre Hospitalier de Cannes Recruiting
Cannes, France, 06400
Contact: Pierre-Marie BERTRAND   
Contact: Alexandre ROBERT   
CHU de Dijon Recruiting
Dijon, France
Contact: Belaid BOUHEMAD   
Centre Hospitalier de Draguignan Recruiting
Draguignan, France, 83300
Contact: Andres Jurado   
Centre Hospitalier de Grasse Recruiting
Grasse, France, 06130
Contact: Pierre-Marie Bertrand   
Contact: Alexandre Robert   
Clinique Ambroise-Paré Recruiting
Neuilly, France
Contact: Lee NGUYEN   
CHU de Nice Recruiting
Nice, France, 06200
Contact: Denis DOYEN    0033492035510,   
Hôpitaux Universitaires Paris Centre - Hôpital Cochin Recruiting
Paris, France, 75014
Contact: Mathieu Jozwiak    0033158412661   
Sub-Investigator: Jonathan MAREY         
CHU de REIMS Recruiting
Reims, France
Contact: Vincent DUPONT   
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Layout table for investigator information
Principal Investigator: Denis DOYEN CHU de NICE - Archet 1
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Nice Identifier: NCT04335162    
Other Study ID Numbers: 20reamedcovid01
First Posted: April 6, 2020    Key Record Dates
Last Update Posted: November 24, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: no data sharing plan has been established.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Embolism
Myocardial Infarction
Acute Coronary Syndrome
Venous Thromboembolism
Venous Thrombosis
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Embolism and Thrombosis
Lung Diseases
Respiratory Tract Diseases